search
Back to results

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (FLAGSHP-1)

Primary Purpose

Advanced or Metastatic Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
ERAS-601
Cetuximab
Pembrolizumab
Sponsored by
Erasca, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced or Metastatic Solid Tumors focused on measuring SHP2, PTPN11, solid tumor, advanced solid tumor, metastatic solid tumor, neoplasms, solid malignancies, targeted therapy, colorectal cancer, CRC, head and neck squamous cell carcinoma, HPV Negative HNSCC, molecular alterations, cetuximab, Erbitux, Chordoma

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Willing and able to give written informed consent
  • Have histologically or cytologically confirmed advanced or metastatic solid tumor
  • There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy
  • Able to swallow oral medication
  • Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  • Adequate cardiovascular, hematological, liver, and renal function
  • Willing to comply with all protocol-required visits, assessments, and procedures

Exclusion Criteria:

  • Previous treatment with a SHP2 inhibitor
  • Documented PTPN11 mutations
  • Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-601
  • Received prior palliative radiation within 7 days of Cycle 1, Day 1
  • Have primary central nervous system (CNS) disease or known active CNS metastases and/or carcinomatous meningitis
  • Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
  • Active, clinically significant interstitial lung disease or pneumonitis
  • History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose of study treatment
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO
  • Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
  • Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial

Sites / Locations

  • University of Alabama at BirminghamRecruiting
  • University of California, San DiegoRecruiting
  • Sarah Cannon Research Institute (Florida Cancer Specialists)Recruiting
  • Massachusetts General HospitalRecruiting
  • Washington UniversityRecruiting
  • Comprehensive Cancer Centers of NevadaRecruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • University of North CarolinaRecruiting
  • University of CincinnatiRecruiting
  • University of PennsylvaniaRecruiting
  • Sarah Cannon Research Institute (Tennessee Oncology)Recruiting
  • Mary Crowley Cancer ResearchRecruiting
  • The University of Texas MD Anderson Cancer CenterRecruiting
  • Peter MacCallum Cancer CentreRecruiting
  • Linear Clinical ResearchRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Dose Escalation (Part A): ERAS-601 monotherapy

Dose Escalation (Part B): ERAS-601 monotherapy

Dose Escalation (Part C): ERAS-601 monotherapy

Dose Escalation and Dose Expansion (Part D): ERAS-601 in combination with cetuximab

Dose Escalation and Dose Expansion (Part E): ERAS-601 in combination with pembrolizumab

Arm Description

ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.

ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.

ERAS-601 will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent.

ERAS-601 will be administered in sequential ascending doses with cetuximab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC).

ERAS-601 will be administered in sequential ascending doses with pembrolizumab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or non small cell lung cancer (NSCLC).

Outcomes

Primary Outcome Measures

Dose Limiting Toxicities (DLT)
Based on toxicities observed
Maximum tolerated dose (MTD)
Based on toxicities observed
Recommended dose (RD)
Based on toxicities observed
Adverse Events
Incidence and severity of treatment-emergent AEs and serious AEs
Plasma concentration (Cmax)
Maximum plasma concentration of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Time to achieve Cmax (Tmax)
Time to achieve maximum plasma concentration of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Area under the curve
Area under the plasma concentration-time curve of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Half-life
Half-life of ERAS-601 and cetuximab or pembrolizumab (if applicable)

Secondary Outcome Measures

Objective Response Rate (ORR)
Based on assessment of radiographic imaging per RECIST version 1.1
Duration of Response (DOR)
Based on assessment of radiographic imaging per RECIST version 1.1
Time to Response (TTR)
Based on assessment of radiographic imaging per RECIST version 1.1

Full Information

First Posted
December 11, 2020
Last Updated
September 19, 2023
Sponsor
Erasca, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04670679
Brief Title
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Acronym
FLAGSHP-1
Official Title
An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2020 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Erasca, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.
Detailed Description
This is a first-in-human, Phase 1/1b, open-label, multicenter clinical study of ERAS-601 as a monotherapy and in combination with other cancer therapies. The study will commence with dose escalation of ERAS-601 monotherapy, followed by dose escalation of ERAS-601 in combination with other cancer therapies. Once the monotherapy MTD and/or RD has been determined, then dose expansion of ERAS-601 monotherapy may commence with enrollment of study participants with advanced or metastatic solid tumors harboring specific molecular alterations. Once the combination therapy MTD and/or RD has been determined, then dose expansion of that combination may commence with enrollment of study participants with advanced or metastatic solid tumors harboring specific molecular alterations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced or Metastatic Solid Tumors
Keywords
SHP2, PTPN11, solid tumor, advanced solid tumor, metastatic solid tumor, neoplasms, solid malignancies, targeted therapy, colorectal cancer, CRC, head and neck squamous cell carcinoma, HPV Negative HNSCC, molecular alterations, cetuximab, Erbitux, Chordoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose Escalation (Part A): ERAS-601 monotherapy
Arm Type
Experimental
Arm Description
ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
Arm Title
Dose Escalation (Part B): ERAS-601 monotherapy
Arm Type
Experimental
Arm Description
ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
Arm Title
Dose Escalation (Part C): ERAS-601 monotherapy
Arm Type
Experimental
Arm Description
ERAS-601 will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent.
Arm Title
Dose Escalation and Dose Expansion (Part D): ERAS-601 in combination with cetuximab
Arm Type
Experimental
Arm Description
ERAS-601 will be administered in sequential ascending doses with cetuximab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC).
Arm Title
Dose Escalation and Dose Expansion (Part E): ERAS-601 in combination with pembrolizumab
Arm Type
Experimental
Arm Description
ERAS-601 will be administered in sequential ascending doses with pembrolizumab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or non small cell lung cancer (NSCLC).
Intervention Type
Drug
Intervention Name(s)
ERAS-601
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Cetuximab
Other Intervention Name(s)
Erbitux
Intervention Description
Administered via intravenous infusion
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda
Intervention Description
Administered via intravenous infusion
Primary Outcome Measure Information:
Title
Dose Limiting Toxicities (DLT)
Description
Based on toxicities observed
Time Frame
Study Day 1 up to Day 29
Title
Maximum tolerated dose (MTD)
Description
Based on toxicities observed
Time Frame
Study Day 1 up to Day 29
Title
Recommended dose (RD)
Description
Based on toxicities observed
Time Frame
Study Day 1 up to Day 29
Title
Adverse Events
Description
Incidence and severity of treatment-emergent AEs and serious AEs
Time Frame
Assessed up to 24 months from time of first dose
Title
Plasma concentration (Cmax)
Description
Maximum plasma concentration of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Time Frame
Study Day 1 up to Day 29
Title
Time to achieve Cmax (Tmax)
Description
Time to achieve maximum plasma concentration of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Time Frame
Study Day 1 up to Day 29
Title
Area under the curve
Description
Area under the plasma concentration-time curve of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Time Frame
Study Day 1 up to Day 29
Title
Half-life
Description
Half-life of ERAS-601 and cetuximab or pembrolizumab (if applicable)
Time Frame
Study Day 1 up to Day 29
Secondary Outcome Measure Information:
Title
Objective Response Rate (ORR)
Description
Based on assessment of radiographic imaging per RECIST version 1.1
Time Frame
Assessed up to 24 months from time of first dose
Title
Duration of Response (DOR)
Description
Based on assessment of radiographic imaging per RECIST version 1.1
Time Frame
Assessed up to 24 months from time of first dose
Title
Time to Response (TTR)
Description
Based on assessment of radiographic imaging per RECIST version 1.1
Time Frame
Assessed up to 24 months from time of first dose
Other Pre-specified Outcome Measures:
Title
Pharmacodynamic assessment
Description
Assessment of phosphorylated ERK (pERK) inhibition in PBMCs or tumor tissue by IHC or immunofluorescence.
Time Frame
Assessed up to 24 months from time of first dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Willing and able to give written informed consent Have histologically or cytologically confirmed advanced or metastatic solid tumor There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy Able to swallow oral medication Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 Adequate cardiovascular, hematological, liver, and renal function Willing to comply with all protocol-required visits, assessments, and procedures Exclusion Criteria: Previous treatment with a SHP2 inhibitor Documented PTPN11 mutations Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-601 Received prior palliative radiation within 7 days of Cycle 1, Day 1 Have primary central nervous system (CNS) disease or known active CNS metastases and/or carcinomatous meningitis Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption Active, clinically significant interstitial lung disease or pneumonitis History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose of study treatment History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Erasca Clinical Team
Phone
+1-858-465-6511
Email
clinicaltrials@erasca.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Les Brail, PhD
Organizational Affiliation
Clinical Development
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Recruiting
Facility Name
University of California, San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Name
Sarah Cannon Research Institute (Florida Cancer Specialists)
City
Sarasota
State/Province
Florida
ZIP/Postal Code
34232
Country
United States
Individual Site Status
Recruiting
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Name
Comprehensive Cancer Centers of Nevada
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89014
Country
United States
Individual Site Status
Recruiting
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Name
Sarah Cannon Research Institute (Tennessee Oncology)
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Name
Mary Crowley Cancer Research
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Peter MacCallum Cancer Centre
City
Melbourne
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Name
Linear Clinical Research
City
Perth
State/Province
Western Australia
Country
Australia
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs